Eight major innovations make their CIIE debut, accelerating access to global healthcare innovation for patients in China
As the Healthy China Initiative continues to advance, faster access to innovative medicines and advanced diagnostic and treatment technologies is opening new possibilities for meeting patients' growing health needs. As one of the first multinational pharmaceutical companies to achieve simultaneous global development and registration of new medicines in China, Bayer continues to increase its innovation investment in the country and uses the CIIE as a platform to accelerate the introduction of global innovations.
At this year's CIIE, Bayer's Pharmaceuticals Division is showcasing innovations across cardiovascular and cerebrovascular disease, oncology, neurology, ophthalmology, women's health and Radiology. Eight major Pharmaceuticals and Radiology innovations are making their CIIE debut, reflecting Bayer's continued commitment from innovative drug development to local manufacturing and supply.
